1. Scrip
  2. >>R&D

Faron Set To Fly As Bexmarilimab Shows Promise

IO Candidate Offers Unique Mode Of Action

 
• By Kevin Grogan

Data have shown that the Finnish firm's bexmarilimab has the potential to be the first macrophage immune checkpoint therapy and big pharma are getting interested in a licensing deal.

Jalkanen_Markku
Markku Jalkanen • Source: Faron

After a couple of years in the doldrums, Faron Pharmaceuticals Oy's star is rising again on the prospects of its next-generation immunotherapy bexmarilimab becoming a blockbuster.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

AstraZeneca’s Truqap Trips Up In Prostate Cancer Study

 
• By Kevin Grogan

The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.